Protein Kinase C Inhibitors as Novel Radiosensitizing Agents in the Treatment of Primary GNAQ Mutant Uveal Melanoma

Abstract

Radiation therapy (RT) is the standard of care approach for treatment of patients with primary uveal melanoma (UM). However, since the tumors are generally radioresistant, large fraction sizes of radiation are required to achieve tumor cell kill, which leads to an increase in normal tissue toxicity and frequently results in vision-threatening radiation complications. Activating somatic mutations in the G protein αq-subunit, GNAQ, have been recently identified to be present in approximately 50% of UM patients.